Physicians who see patients with mitochondrial disease have a practical new tool: the first published care standards to guide clinical care.

This is a game changer for the treatment of pediatric patients battling leukemia and a pivotal milestone in this new era of cellular therapies that treat cancer with a patient’s own immune system.

Newly created videos allow families to see the facilities’ interiors and better understand what will happen during an outpatient visit before their scheduled appointment.

Since its inception in October 2016, the workshop has created recommendations for the 50 most common syndromes that predispose children to cancer and produced 16 position papers.

Thanks to a recent initiative at CHOP, patients newly diagnosed with B-cell and T-cell ALL, and lymphoblastic lymphoma, now go home on average 9 days after diagnosis — that's 3 weeks sooner than previous stays.

Five years after her T-cell therapy for ALL, Emily remains cancer-free. CHOP has since treated more than 170 patients in clinical trials that have seen a 93% remission rate.

A team of researchers at Children's Hospital of Philadelphia has innovated a new womb-like device that may dramatically reduce the effects of prematurity and revolutionize care for these tiny and vulnerable babies.

Dr. Lara Antkowiak identified breastfeeding as a key intervention to vastly improve the ability of a CHOP program to help families prevent illness and promote health in the Dominican Republic.

CHOP Global Health’s David N. Pincus Fellow Henry Welch, MD, working in close collaboration with Botswana’s Ministry of Health, reduced hospitalizations and deaths from rotavirus in children in Botswana.

CHOP's primary care network extends far beyond our region — Starlin is being treated for anemia in a barrio in Consuelo, Dominican Republic through a CHOP Global Health program.